statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Nektar to Announce Financial Results for the First Quarter 2024 on Thursday, May 9, 2024, After Close of U.S.-Based Financial Markets Nektar to Announce Financial Results for the First Quarter 2024...

Nektar to Announce Financial Results for the First Quarter 2024 on Thursday, May 9, 2024, After Close of U.S.-Based Financial Markets

Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune...

Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference

GSA Capital Partners LLP lifted its position in shares of Nektar Therapeutics (NASDAQ:NKTR  Free Report) by 931.5% during the 3rd quarter, according to its most recent disclosure with the SEC...

GSA Capital Partners LLP Increases Position in Nektar Therapeutics (NASDAQ:NKTR)

Nektar Therapeutics (NASDAQ:NKTR  Free Report) had its price target increased by Jefferies Financial Group from $0.50 to $1.00 in a report published on Wednesday, Benzinga reports. Jefferies...

Nektar Therapeutics (NASDAQ:NKTR) Price Target Raised to $1.00

Nektar Therapeutics (NASDAQ:NKTR  Free Report)  Equities research analysts at William Blair lowered their Q1 2024 earnings estimates for shares of Nektar Therapeutics in a report...

William Blair Weighs in on Nektar Therapeutics' Q1 2024 Earnings (NASDAQ:NKTR)

Shares of Nektar Therapeutics (NASDAQ:NKTR  Get Free Report) have been assigned an average recommendation of Hold from the five ratings firms that are presently covering the...

Nektar Therapeutics (NASDAQ:NKTR) Receives $3.33 Average Target Price from Analysts

Nektar Therapeutics (NKTR) Q4 2023 Earnings Call Transcript...

Nektar Therapeutics (NKTR) Q4 2023 Earnings Call Transcript

Nektar Therapeutics Announces Initiation of Phase 2b Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia Areata Nektar Therapeutics Announces Initiation of...

Nektar Therapeutics Announces Initiation of Phase 2b Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia Areata

Nektar Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results Nektar Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results PR Newswire SAN FRANCISCO, March 4, 2024...

Nektar Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results

Nektar Therapeutics Announces $30 Million Private Placement Financing with TCGX Nektar Therapeutics Announces $30 Million Private Placement Financing with TCGX PR Newswire SAN FRANCISCO, March 4...

Nektar Therapeutics Announces $30 Million Private Placement Financing with TCGX

Nektar Therapeutics is a research-based biopharmaceutical company which engages in discovering and developing medicines in areas of unmet medical need. Its research and development pipeline of new investigational drugs includes therapies for oncology, immunology and virology. The firm focuses on using new chemistry approaches to make medicines to treat cancer and autoimmune diseases. The company was founded in 1990 and is headquartered in San Francisco, CA.

Volume	1.14M
52-Wk High	$1.79
52-Wk Low	$0.4126

Period	Estimated	Reported	Surprise	Result
Q1'24	-$0.19	--	--	N/A
Q4'23	-$0.21	-$0.22	-4.54%	MISSED
Q3'23	-$0.20	-$0.24	-21.02%	MISSED
Q2'23	-$0.28	-$0.27	4.08%	BEAT
Q1'23	-$0.25	-$0.73	-194.31%	MISSED

NKTR Nektar Therapeutics

About

Feed

News

Sentiment

Earnings

Fundamentals